Lupus therapy advances after a long quiet period
Late-stage lupus programs across belimumab follow-ons, anifrolumab extensions, and CD19-directed cell therapy are reshaping a long-stagnant therapy landscape.
Systemic lupus erythematosus has had limited new therapy for two decades. The current late-stage pipeline (CD19 cell therapy in severe lupus, type-I interferon receptor agents, novel B-cell depleters) is more promising than at any point since hydroxychloroquine. Real-world adoption depends on rheumatology comfort with cell-therapy referral pathways.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.